Temporal trends in cause of death among Swedish and US men with prostate cancer

Journal of the National Cancer Institute

Volumn 104, Issue 17, 2012, Pages 1335-1342

  Epstein, Mara M ^a,b   Edgren, Gustaf ^a,c   Rider, Jennifer R ^a,b   Mucci, Lorelei A ^a,b   Adami, Hans Olov ^a,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CAUSE OF DEATH; FOLLOW UP; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; CAUSE OF DEATH; HUMANS; MALE; MIDDLE AGED; MORTALITY; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGISTRIES; RISK FACTORS; RISK REDUCTION BEHAVIOR; SEER PROGRAM; SWEDEN; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84866062741     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs299     Document Type: Article

References (40)

1. Meyer MS, Mucci LA, Andersson SO, et al. Homogeneous prostate cancer mortality in the Nordic countries over four decades. Eur Urol. 2010;58(3):427-432.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
3. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94(13):981-990. (Pubitemid 34814727)
4. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101(19):1325-1329.
5. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302(11): 1202-1209.
6. Howlader N, Noone AM, Krapcho M, et al. (Eds). SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011. http://seer.cancer.gov/csr/1975-2009-pops09/. Accessed October 25, 2011.
7. Johansson E, Steineck G, Holmberg L, et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol. 2011;12(9):891-899.
8. Pardo Y, Guedea F, Aguilo F, et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol. 2010;28(31):4687-4696.
9. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250- 1261. (Pubitemid 351439226)
10. Lajous M, Mozaffarian D, Mozaffarian R, Schrag D, Adami HO. Lifestyle prescriptions for cancer survivors and their communities. J Intern Med. 2011;269(1):88-93.
11. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide [database on the Internet]. Lyon, France: International Agency for Research on Cancer. 2010. http://globocan.iarc.fr. Accessed November 15, 2011.
12. World Health Organization. ICD-7. International Statistical Classification of Diseases and Related Health Problems, Seventh Revision. Geneva, Switzerland: World Health Organization; 1955.
13. The National Board of Health and Welfare. Cancer Incidence in Sweden 2005. Stockholm: National Board of Health and Welfare (Socialstyrelsen); 2007.
14. World Health Organization. International Classification of Diseases for Oncology, 3rd ed. (ICD-O-3). Geneva, Switzerland: World Health Organization; 1976.
15. Surveillance, Epidemiology, and End Results (SEER) Program. Research Data (1973-2008), Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. 2011. http://www.seer.cancer.gov. Accessed September 27, 2011.
16. World Health Organization. ICD-8. International Statistical Classification of Diseases and Related Health Problems, Eighth Revision. Geneva, Switzerland: World Health Organization; 1968.
17. World Health Organization. ICD-9. International Statistical Classification of Diseases and Related Health Problems, Ninth Revision. Geneva, Switzerland: World Health Organization; 1975.
18. World Health Organization. ICD-10. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision. Vol. 1-3. Geneva, Switzerland: World Health Organization; 1992-1994.
19. Neppl-Huber C, Zappa M, Coebergh JW, et al. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Ann Oncol. 2012;23(5):1325-1334.
20. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons; 1980.
21. Robbins AS, Chao SY, Fonseca V P. What's the relative risk? A method to directly estimate risk ratios in cohort studies of common outcomes. Ann Epidemiol. 2002;12(7):452-454.
22. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374-383.
23. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273(4):289-294.
24. Savage CJ, Lilja H, Cronin AM, Ulmert D, Vickers AJ. Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening. Cancer Epidemiol Biomarkers Prev. 2010;19(5):1201-1207.
25. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA. 2003;289(11):1414-1420. (Pubitemid 37430309)
26. Jonsson H, Holmstrom B, Duffy SW, Stattin P. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden. Int J Cancer. 2011;129(8):1881-1888.
27. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006;98(16):1134-1141. (Pubitemid 44288788)
28. Sandblom G, Dufmats M, Nordenskjold K, Varenhorst E. Prostate carcinoma trends in three counties in Sweden 1987-1996: results from a population-based national cancer\-register. South-East Region Prostate Cancer Group. Cancer. 2000;88(6):1445-1453. (Pubitemid 30155184)
29. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer\-part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 1999;91(12):1025-1032. (Pubitemid 29293041)
30. Fall K, Stromberg F, Rosell J, Andren O, Varenhorst E. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol. 2008;42(4):352-357.
31. Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368(9548):1673-1679. (Pubitemid 46048554)
32. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371(9626):1783-1789. (Pubitemid 351697954)
33. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-393. (Pubitemid 36159355)
34. Tuomilehto J, Schwarz P, Lindstrom J. Long-term benefits from lifestyle interventions for type 2 diabetes prevention: time to expand the efforts. Diabetes Care. 2011;34(2 suppl):S210-214.
35. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW, Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341(15):1097-1105. (Pubitemid 29466221)
36. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-1638. (Pubitemid 36459468)
37. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004;328(7455):1519.
38. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364(18):1708-1717.
39. Sonpavde G. Radical prostatectomy versus watchful waiting. N Engl J Med. 2005;353(12):1298-300.
40. Wilt T. The VA/NCI/AHRQ CSP #407: Prostate Cancer Intervention Versus Observation Trial (PIVOT): main results from a randomized trial comparing radical prostatectomy to watchful waiting in men with clinically localized prostate cancer. Paper presented at American Urological Association Annual Meeting; May 2011; Washington, DC.